

Clinical features of severe patients infected with 2019 ...

<https://pubmed.ncbi.nlm.nih.gov/32566603>

Clinical features of **severe** patients infected with 2019 novel coronavirus: a systematic review and meta-analysis. Severe patients with COVID-19 had more risk of clinical characteristics and...

Cited by: **14** Author: Daozheng Huang, Xingji Lian, Feier S...

Publish Year: 2020

See more

Coronavirus disease (COVID-19)

<https://www.who.int/news-room/q-a-detail/coronavirus-disease-covid-19> ▾

COVID-19 is the disease caused by a new coronavirus called SARS-CoV-2. WHO first learned of this new virus on 31 December 2019, following a report of a cluster of cases of lung

[Interventions for treatment of COVID-19: A living ...](#)

<https://pubmed.ncbi.nlm.nih.gov/32941437>

Background: Coronavirus disease 2019 (COVID-19) is a rapidly spreading disease that has caused extensive burden to individuals, families, countries, and the world. Effective treatments of COVID-19 are urgently needed. Methods and findings: This is the first edition of a living systematic review of randomized clinical trials comparing the effects of all treatment interventions for participants ...

Cited by: 9

Author: Sophie Juul, Emil Eik Nielsen, Joshua Fe...

Publish Year: 2020

[Mortality Benefit of Remdesivir in COVID-19: A Systematic ...](#)

<https://pubmed.ncbi.nlm.nih.gov/33585508>

Importance/Background: During current public health emergency of COVID-19 pandemic, repurposing of existing antiviral drugs may be an efficient strategy since there is no proven effective treatment. Published literature shows Remdesivir has broad-spectrum antiviral activity against numerous R ...

[Epidemiology, clinical characteristics and treatment of ...](#)

<https://bmjopen.bmj.com/content/11/1/e042008> ▾

Jan 01, 2021 · Within the reported critically ill COVID-19 data, there is substantial variation in population characteristics, duration of follow-up and interventions assessed across studies due to differences in design, case-mix and data quality.19 20 Preliminary epidemiological data, reports and retrospective observational data suggest a COVID-19 case fatality rate ranging from 2.3% to 7.2%.13 21 22 The leading cause of mortality ...

Author: Lazar Milovanovic, Erin Hessey, Megh...

Publish Year: 2021

[Mortality Benefit of Remdesivir in COVID-19: A Systematic ...](#)

<https://www.frontiersin.org/articles/10.3389/fmed.2020.606429> ▾

Jan 27, 2021 · - Our systematic review and meta-analysis provides a detailed overview of existing literature on Remdesivir in COVID-19 to evaluate the mortality benefits and adverse events. Introduction The city of Wuhan in China initially noted and reported the first case of coronavirus, termed as SARS-CoV-2, in December 2019 (1).

Author: Vikas Bansal, Kiran S. Mahapure, Ab...

Publish Year: 2021

[Proanostic factors for severity and mortality in patients ...](#)

Name of Journal: *World Journal of Meta-Analysis*

Manuscript NO: 62875

Manuscript Type: SYSTEMATIC REVIEWS

Mortality of critical care interventions in the COVID-19: A systematic review

Davis J *et al.* Mortality in COVID-19

Joshua Davis, Rebecca Leff, Anuj Patel, Sriram Venkatesan

Abstract

BACKGROUND

The novel coronavirus severe acute respiratory syndrome coronavirus 2 is associated with a severe disease known as coronavirus disease 2019 (COVID-19). A small

Match Overview

国内版 国际版

Mortality of critical care interventions in the COVID-19: A systematic



ALL

IMAGES

VIDEOS

2,550,000 Results

Any time ▾

Epidemiology, clinical characteristics and treatment of ...

<https://pubmed.ncbi.nlm.nih.gov/33402406>

Within the framework of a living systematic review, the search and data analysis will be updated every 6 months. Ethics and dissemination: Our systematic review will synthesise literature on risk factors and **interventions** associated with **mortality** in **critically ill patients** with COVID-19. **Results** will be presented at national and international conferences and submitted for peer-reviewed publication.

Interventions for treatment of COVID-19: A living ...

<https://pubmed.ncbi.nlm.nih.gov/32941437>

Background: Coronavirus disease 2019 (COVID-19) is a rapidly spreading disease that has caused extensive burden to individuals, families, countries, and the world. Effective treatments of COVID-19 are urgently needed. Methods and findings: This is the first edition of a living **systematic review** of randomized clinical trials comparing the effects of all treatment **interventions** for participants ...

Cited by: 9

Author: Sophie Juul, Emil Eik Nielsen, Joshua Fe...

Publish Year: 2020

Factors associated with disease severity and mortality ...

<https://pubmed.ncbi.nlm.nih.gov/33206661>

Background: Understanding the factors associated with **disease severity** and **mortality** in **Coronavirus disease** (COVID-19) is imperative to effectively triage patients. We performed a systematic review to determine the demographic, clinical, laboratory and radiological factors associated with **severity** and **mortality** in COVID-19.

Cited by: 3

Author: Vignesh Chidambaram, Nyan Lynn Tun, ...

Publish Year: 2020

Epidemiology, clinical characteristics and treatment of ...

<https://bmjopen.bmj.com/content/11/1/e042008> ▾

Jan 01, 2021 · Within the reported **critically ill COVID-19 data**, there is substantial variation in population characteristics, duration of follow-up and **interventions** assessed across studies due to differences in design, case-mix and data quality.^{19 20} Preliminary epidemiological data, reports and retrospective observational data suggest a **COVID-19 case fatality rate** ranging from 2.3% to 7.2%.^{13 21 22} The leading cause of **mortality** ...

Author: Lazar Milovanovic, Erin Hessey, Megh...

Publish Year: 2021